

ID NOs: 27-40, N-terminally coupled to a polyethylene glycol moiety, wherein the interferon-beta-1a is coupled to the polyethylene glycol moiety by a labile bond, wherein the labile bond is cleavable by biochemical hydrolysis and/or protcolysis.

54. **(newly added)** An interferon-beta composition according to claims 41, wherein the polymer has a molecular weight of from about 5 to 40 kilodaltons.
55. **(newly added)** An interferon-beta composition according to claims 49, wherein the polymer has a molecular weight of from about 5 to 40 kilodaltons.
56. **(newly added)** A interferon-beta composition according to claims 53, wherein the polymer has a molecular weight of from about 5 to 40 kilodaltons.
57. **(newly added)** A pharmaceutical composition comprising the interferon-beta composition of claim 54.

Remarks

Any questions arising from this submission may be directed to the undersigned at (617) 832-1000.

The Commissioner is hereby authorized to charge any under-payments or credit any over-payments to our Deposit Account No. 06-1448.

Respectfully Submitted,

By: 

Beth E. Arnold
Reg. No. 35,430
Attorney for Applicants

Date: July 27, 2004
Customer No: 25181
Patent Group
Foley Hoag LLP
World Trade Center West
155 Seaport Blvd.
Boston, MA 02210-2600
Tel. (617) 832-1000
Fax. (617) 832-7000